Potential therapeutics for SARS

Stable Identifier
R-HSA-9679191
DOI
Type
Pathway
Species
Homo sapiens
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

The search for drugs to prevent or reduce the severity of human infection with SARS-CoV-1 or SARS-CoV-2 has centered on ones that are effective in treatment of human infections with other RNA viruses or in diminishing cytokine storms and other pathologies due to destructive host reactions. The interactions of a large number of these candidate drugs with their known viral and human protein targets are annotated, as are some drugs that inhibit Cytochrome P450 (CYP) oxidoreductases to prolong the plasma half-lives of antiviral drugs. In addition, effects of these drugs on unrelated essential human proteins, that might limit their use in vivo, are annotated.

A notable success of this search is a combination treatment, Paxlovid (NCT04960202), involving ritonavir, an inhibitor of CYP3A4 and CYP2B6 oxidoreductases, and nirmatrelvir, an inhibitor of SARS-CoV-2 3CLp protease, to block steps in maturation of viral replicase proteins (Hashemian et al. 2023).

Literature References
PubMed ID Title Journal Year
32256547 Clinical trials on drug repositioning for COVID-19 treatment

Rosa, SGV, Santos, WC

Rev. Panam. Salud Publica 2020
37018987 Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Mirzaei, H, Bannazadeh Baghi, H, Sadri Nahand, J, Taghizadieh, M, Hashemian, SMR, Sheida, A, Hamblin, MR, Memar, MY, Asemi, Z

Biomed Pharmacother 2023
32205870 Coronavirus puts drug repurposing on the fast track

Harrison, C

Nat. Biotechnol. 2020
Participants
Events
Participates
Disease
Name Identifier Synonyms
viral infectious disease DOID:934 Viral disease, virus infection, virus infection
Authored
Reviewed
Created
Cite Us!